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Abstract
microRNAs (miRNAs) are evolutionarily conserved, endogenous, small, noncoding RNA molecules
of about 22 nucleotides in length that function as posttranscriptional gene regulators. They are
deemed to play a crucial role in the initiation and progression of human cancer, and those with a
role in cancer are designated as oncogenic miRNAs (oncomiRs). For example, miR-15 and miR-16
induce apoptosis by targeting Bcl2. miRNAs from the miR-17-92 cluster modulate tumor formation
and function as oncogenes by influencing the translation of E2F1 mRNA. miR-21  modulates
gemcitabine-induced apoptosis by phosphatase and tensin homolog deleted on chromosome 10-
dependent activation of PI 3-kinase signaling. miR-34a acts as a suppressor of neuroblastoma
tumorigenesis by targeting the mRNA encoding E2F3 and reducing E2F3 protein levels. The
chromosomal translocations associating with human tumors disrupt the repression of High
mobility group A2 by let-7 miRNA. In addition, the oncomiRs expression profiling of human
malignancies has also identified a number of diagnostic and prognostic cancer signatures. This
article introduces the roles of oncomiRs in neoplasm development, progression, diagnosis,
prognostication, as well as their mechanism of actions on target mRNAs and the functional
outcomes of their actions on mRNAs. The paper ends with a brief perspective to the future of
oncomiRs.
Introduction
microRNAs (miRNAs) are evolutionarily conserved,
endogenous, small, noncoding RNA molecules of about
22 nucleotides in length that function as posttranscrip-
tional gene regulators [1]. They are encoded in the
genome and are generally transcribed by RNA polymerase
II. miRNAs work via RNA-induced silencing complexes,
targeting them to messenger RNAs where they either
repress translation or direct destructive cleavage [2].
Recent evidences have shown that miRNAs have diverse
functions, including the regulation of cellular develop-
ment, differentiation, proliferation and apoptosis. The
first miRNA was described in 1993, in which the C. elegans
heterochronic gene lin-4 encoded small RNAs with anti-
sense complementarity to lin-14 [3]. It is estimated that
vertebrate genomes encode up to 1,000 unique miRNAs
[4], which are predicted to regulate expression of at least
30% of genes [5]. Though more than 530 miRNAs have
been identified in human, much remains to be under-
stood about their precise cellular function and role in the
development of diseases. Recent evidences indicate that
miRNAs can function as tumor suppressors and onco-
genes, and the miRNAs with a role in cancer are desig-
nated as oncogenic miRNAs (oncomiRs). This article
introduces the roles of oncomiRs in neoplasm develop-
ment, progression, diagnosis, prognostication, as well as
their mechanism of actions on target mRNAs and the
functional outcomes of their actions on mRNAs.
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microRNAs experiment
miRNA microarray is a high-throughput approach to
study the expression of miRNAs in cultured cells or tis-
sues. Unlike the traditional cDNA microarray expression
profiling, RNA samples used for miRNA microarray
hybridization need to be enriched for small RNAs. Usu-
ally, the first step of a miRNA microarray experiment is the
isolation of total RNA and the enrichment or direct isola-
tion of small RNA. The miRNAs are then labeled and
cleaned-up, following with miRNA hybridization to
arrays spotted with miRNA probes. After washes and scan-
ning, the differential miRNAs are identified. Subsequent
validation is recommended using Northern blot, quanti-
tative reverse transcription-polymerase chain reaction
(qRT-PCR), or other analytical methods. The recent devel-
opment of highly efficient labeling method and novel
microarray probe design enable direct label as low as 120
ng of total RNA using Cy3 or Cy5, without fractionation
or amplification, to produce precise and accurate meas-
urements that span a linear dynamic range from 0.2 amol
to 2 fmol of input miRNA. The assay is also applicable for
formalin-fixed paraffin-embedded samples [6].
microRNAs and cancers
It has been reported that miRNAs play a crucial role in the
initiation and progression of human cancer. Deregulation
of oncomiRs is associated with genetic or epigenetic alter-
ations, including deletion, amplification, point mutation
and aberrant DNA methylation [7]. Their expression pro-
filing of human malignancies has identified signatures
involving in cancer development, progression, diagnosis
and prognosis (Table 1).
The role of microRNAs in tumorigenesis
Calin et al. first made the connection between microRNAs
and cancer by showing that miR-15  and  miR-16  are
located at chromosome 13q14, a region deleted in more
than half of B-cell chronic lymphocytic leukemia (CLL).
Detailed deletion and expression analysis showed that
miR-15 and miR-16 are located within a 30 kb region of
loss in CLL, and that both genes were deleted or downreg-
ulated in approximately 68% of CLL cases [8]. They fur-
ther showed that miR genes were frequently located in
cancer-associated genomic regions or in fragile sites. The
full complement of miRNAs in a genome might be exten-
sively involved in cancers [9]. Bottoni et al. found that
miR-15a and miR-16-1 were expressed at lower levels in
pituitary adenomas as compared to normal pituitary tis-
sue. Their expression was inversely correlated with tumor
diameter and with arginyl-tRNA synthetase expression,
but was directly correlated with p43 secretion, suggesting
that these miRNAs might influence tumor growth [10].
Cimmino et al. then demonstrated that miR-15a and miR-
16-1 expressions were inversely correlated to Bcl2 expres-
sion in CLL and that both miRNAs negatively regulated
Bcl2 at a posttranscriptional level. Bcl2 repression by these
miRNAs induced apoptosis in a leukemic cell line model.
Therefore miR-15 and miR-16 were natural antisense Bcl2
interactors that could be used for therapy of Bcl2-overex-
pressing tumors [11]. Recently, Garzon et al. showed that
all-trans retinoic acid (ATRA) downregulation of Bcl2 and
Ras was correlated with the activation of miR-15a/miR-16-
1 [12].
Amplification and overexpression of the miR-17-92,
which comprised 7 miRNAs and resided in intron 3 of the
C13orf25 gene at 13q31.3, has been reported with point-
ers to functional involvement in the development of lym-
phoma and lung cancer. He et al. compared B-cell
lymphoma samples and cell lines to normal tissues, and
found that the levels of the primary or mature miRNAs
derived from the miR-17-92 locus were often substantially
increased in cancer cells. Their studies indicated that miR-
NAs could modulate tumor formation and function as
oncogenes, implicating the miR-17-92 cluster as a poten-
tial human oncomicroRNAs (oncomiRs) [13]. O'Donnell
et al. demonstrated that c-Myc activated expression of a set
of 6 miRNAs on human chromosome 13 that was tied to
the development of human lymphoma. It was found that
the expression of E2F1 was negatively regulated by miR-
17-5p and miR-20a in HeLa cells. Their findings revealed a
mechanism through which the c-Myc protein simultane-
ously activated E2F1 transcription and limited its transla-
tion, allowing a tightly controlled proliferative signal [14].
Woods et al. proposed a model whereby miR-17-92 pro-
moted cell proliferation by shifting the E2F transcrip-
tional balance away from the pro-apoptotic E2F1 and
toward the proliferative E2F3 transcriptional network
[15].
On the other hand, Hayashita et al. found that miR-17-92
was markedly overexpressed in lung cancer, especially
with small-cell lung cancer. Their findings suggested that
marked overexpression of the miR-17-92  cluster with
occasional gene amplification might play a role in the
development of lung cancer and that the C13orf25 gene
might well be serving as a vehicle in this regard [16]. Mat-
subara et al. showed that inhibition of miR-17-5p and miR-
20a with antisense oligonucleotides could induce apopto-
sis selectively in lung cancer cells overexpressing miR-17-
92, suggesting the possibility of oncomiR addiction to
expression of these miRNAs in a subset of lung cancers.
Their discoveries contributed towards better understand-
ing of the oncogenic roles of miR-17-92, which might ulti-
mately lead to the future translation into clinical
applications [17].
Iorio et al. showed that miRNAs were aberrantly expressed
in human breast cancer compared with normal breast tis-
sue, with the most significantly downregulated miRNAsMolecular Cancer 2007, 6:60 http://www.molecular-cancer.com/content/6/1/60
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being miR-10b, miR-125b and miR-145, whereas the most
significantly upregulated miRNAs being miR-21 and miR-
155. The miRNA expression was also found to be corre-
lated with specific breast cancer biopathologic features,
such as estrogen and progesterone receptor expression,
tumor stage, vascular invasion or proliferation index [18].
Si et al. found that miR-21 was highly overexpressed in
breast tumors compared to the matched normal breast tis-
sues. They found that the anti-miR-21-mediated cell
growth inhibition was associated with increased apopto-
sis and decreased cell proliferation. Their results suggested
that miR-21 functioned as an oncogene and modulated
tumorigenesis through regulation of genes such as Bcl2
and it might serve as a novel therapeutic target [19]. Zhu
et al. performed two-dimensional differentiation in-gel
electrophoresis of tumors treated with anti-miR-21 and
identified the tumor suppressor tropomyosin 1 as a
potential miR-21 target. Downregulation of tropomyosin
1 in breast cancer by miR-21 might explain why suppres-
sion of miR-21 could inhibit tumor growth, further sup-
porting the notion that miR-21 functions as an oncogene
[20]. Meng et al. identified miR-21 was also highly overex-
pressed in malignant cholangiocytes. Inhibition of miR-21
increased sensitivity to gemcitabine, it modulated gemcit-
abine-induced apoptosis by phosphatase and tensin
homolog deleted on chromosome 10-dependent activa-
tion of PI 3-kinase signaling [21]. Tran et al. found that
miR-21 was highly expressed in the head and neck cancer
cell lines. Several tumor suppressor genes were identified
to be potential targets of miRNAs, including kinesin fam-
ily member 1B isoform alpha, hypermethylated in cancer
2 and pleomorphic adenoma gene 1 [22].
Costinean et al. showed that E(mu)-mmu-miR-155 trans-
genic mice exhibited preleukemic pre-B-cell proliferation
evident in spleen and bone marrow, followed by frank B-
Table 1: The role of microRNAs in cancers
microRNAs Tumorigenesis Diagnosis Prognosis
miR-9 Neuroblastoma
miR-10b Breast cancer
miR-15, miR-15a Leukemia, pituitary adenoma
miR-16, miR-16-1 Leukemia, pituitary adenoma
miR-17-5p, miR-17-92 Lung cancer, lymphoma
miR-20a Lymphoma, lung cancer
miR-21 Breast cancer, 
cholangiocarcinoma, head & neck 
cancer, leukemia, cervical cancer
Pancreatic cancer
miR-29, miR-29b Leukemia, cholangiocarcinoma
miR-31 Colorectal cancer
miR-34a Pancreatic cancer Neuroblastoma
miR-96 Colorectal cancer
miR-98 Head & neck cancer
miR-103 Pancreatic cancer
miR-107 Leukemia, pancreatic cancer
miR-125a, miR-125b Neuroblastoma, breast cancer
miR-128 Glioblastoma
miR-133b Colorectal cancer
miR-135b Colorectal cancer
miR-143 Colon cancer, cervical cancer
miR-145 Breast cancer, colorectal cancer
miR-146 Thyroid carcinoma
miR-155 Breast cancer, leukemia, 
pancreatic cancer
Lung cancer
miR-181, miR-181a, miR-181b, miR-
181c
Leukemia, glioblastoma, thyroid 
carcinoma
miR-183 Colorectal cancer
miR-184 Neuroblastoma
miR-196a-2 Pancreatic cancer
miR-221 Glioblastoma, thyroid carcinoma Pancreatic cancer
miR-222 Thyroid carcinoma
miR-223 Leukemia
miR-301 Pancreatic cancer
miR-376 Pancreatic cancer
let-7, let-7a, let-7a-1, hsa-let-7a-2, let-
7a-3
Lung cancer, colon cancer Lung cancerMolecular Cancer 2007, 6:60 http://www.molecular-cancer.com/content/6/1/60
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cell malignancy. Their findings indicated that miR-155
could induce polyclonal expansion, favoring the capture
of secondary genetic changes for full transformation [23].
Using miRNA cloning and qRT-PCR of mature miRNAs,
Fulci et al. demonstrated that miR-21 and miR-155 were
dramatically overexpressed in CLL patients [24]. Besides,
Roldo et al. showed that the expression of miR-103 and
miR-107, associating with a lack of miR-155 expression,
could discriminate pancreatic tumors from normal pan-
creas. Their results suggested that the alteration in miRNA
expression was related to endocrine and acinar neoplastic
transformation [25].
Felli et al. demonstrated that treatment of CD34+ progen-
itors with miR-221 and miR-222 caused impaired prolifer-
ation and accelerated differentiation of erythropoietic
cells, coupled with the downmodulation of Kit protein.
The decline of miR-221 and miR-222 during exponential
erythropoietic growth unblocked Kit protein production
at mRNA level, thus leading to expansion of early eryth-
roblasts [26]. He et al. also showed that miR-146, miR-221
and miR-222 distinguished unequivocally between papil-
lary thyroid carcinoma (PTC) and normal thyroid. The
upregulation of these miRNAs was strongest associated
with a dramatic loss of Kit transcript and its protein.
Sequence changes in genes targeted by these miRNAs
could contribute to the regulation of Kit involved in PTC
pathogenesis [27]. Analyzing the genome-wide miRNA
expression profile in human PTCs using microarray, Pal-
lante et al. detected a significant increase of miR-181b,
miR-221 and miR-222 in the comparison of PTCs with
normal thyroid tissue. Further confirmation by Northern
blot analysis and qRT-PCR, their results suggested miRNA
deregulation as an important event in thyroid cell trans-
formation [28].
The analysis of both glioblastoma tissues and glioblast-
oma cell lines allowed Ciafre et al. to identify a group of
miRNAs whose expression was significantly altered in the
tumor. miR-221 was strongly upregulated, whereas miR-
128, miR-181a, miR-181b and miR-181c were downregu-
lated in glioblastoma [29]. Pekarsky et al. discovered that
the expression levels of miR-29  and  miR-181  were
inversely correlated with Tcl1  expression in CLL. Their
results showed that miR-29 and miR-181 might be candi-
dates for therapeutic agents in CLL overexpressing Tcl1
[30]. By in silico analysis, Mott et al. identified a putative
target site in the Mcl1 mRNA and found that miR-29b was
downregulated in malignant cells, consistent with Mcl1
protein upregulation. Enforced miR-29b  expression
reduced Mcl1 protein expression in the KMCH cholangi-
ocarcinoma cells, thus miR-29 was an endogenous regula-
tor of Mcl1 protein expression [31].
Examined by RT-PCR, Bandres et al. identified 13 signifi-
cantly deregulated mature miRNAs in colorectal cancer,
including miR-31, miR-96, miR-133b, miR-135b, miR-145
and miR-183. In addition, the expression level of miR-31
was correlated with the stage of colorectal cancer [32].
Akao et al. found that miR-143 and miR-145 expression
levels were extremely reduced in the colon cancer cells.
The transfection of each precursor miRNA into the cells
demonstrated a significant growth inhibition in human
colon cancer DLD-1 and SW480 cells, whereas Erk5 was
determined to be the target gene of miR-143 [33].
Laneve et al. showed that miR-9, miR-125a and miR-125b
acted in an additive manner by repressing the truncated
isoform of the neurotrophin receptor tropomyosin-
related kinase C. They found that the downregulation of
this isoform was critical for regulating neuroblastoma cell
growth [34].In vitro functional studies of neuroblastoma
cell lines indicated that miR-184 played a significant role
in apoptosis. Chen and Stallings suggested that neuroblas-
toma derived Myc myelocytomatosis viral related onco-
gene might mediate a tumorigenic effect through directly
or indirectly regulating the expression of miRNAs that
were involved with neural cell differentiation and/or
apoptosis [35].
Welch  et al. showed that miR-34a  on chromosome
1p36.23 was generally expressed at lower levels in unfavo-
rable primary neuroblastoma tumors relative to normal
tissue. miR-34a directly targeted the mRNA encoding E2F3
and significantly reduced E2F3 protein levels. Their results
suggested that miR-34a acted as a suppressor of neuroblas-
toma tumorigenesis [36]. Chang et al. showed that miR-
34a was frequently absent in pancreatic cancer cells. They
demonstrated that this miRNA was directly transactivated
by p53. miR-34a-responsive genes were highly enriched
for those that regulated cell-cycle progression, apoptosis,
DNA repair and angiogenesis. It was likely that an impor-
tant function of miR-34a was the modulation and fine-
tuning of the gene expression program initiated by p53
[37].
Nervi et al. found that the expression level of miR-223 was
correlated with the differentiation fate of myeloid precur-
sors. The activation of both pathways of transcriptional
regulation by the myeloid lineage-specific transcription
factor CCAAT/enhancer-binding protein-α (C/EBPa) and
posttranscriptional regulation by miR-223  appeared
essential for granulocytic differentiation and clinical
response of acute promyelocytic leukemia blasted to
ATRA [38]. Using miRNA microarray platform and qRT-
PCR, Garzon et al. reported the expression of miRNAs in
acute promyelocytic leukemia patients and cell lines dur-
ing ATRA treatment. They found upregulation of miR-107
targeted nuclear factor 1-A, a gene involving miR-223 andMolecular Cancer 2007, 6:60 http://www.molecular-cancer.com/content/6/1/60
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C/EBPa in a regulatory loop during granulocytic differen-
tiation. Besides, ATRA downregulation of Ras  and Bcl2
was shown to correlate with the activation of let-7a
miRNA [12].
Johnson et al. showed that the let-7 miRNA family nega-
tively regulated let-60/Ras. Loss of let-60/Ras suppressed
let-7  miRNA complementary sites, restricting reporter
gene expression in a let-7-dependent manner. let-7 miRNA
expression was lower in lung tumors than in normal lung
tissue, while Ras protein was significantly higher in lung
tumors, providing a possible mechanism for let-7 miRNA
in cancer [39]. Akao et al. found that the levels of Ras and
c-Myc proteins in let-7  miRNA low-expressing DLD-1
human colon cancer cells were lowered after the transfec-
tion with let-7a-1 precursor miRNA, whereas the levels of
both of their mRNAs remained almost unchanged. Their
findings suggested the involvement of let-7 miRNA in the
growth of colon cancer cells [40]. Meng et al. demon-
strated that let-7a miRNA was upregulated and contrib-
uted to the survival effects of enforced Interleukin-6
activity in malignant human cholangiocytes. It contrib-
uted to the constitutively increased phosphorylation of
the signal transducers and activators of transcription-3
factors by a mechanism involving neurofibromatosis 2
[41]. Brueckner et al. showed that the human let-7a-3 pre-
cursor miRNA on chromosome 22q13.31 was associated
with a CpG island. They identified let-7a-3  precursor
miRNA as an epigenetically regulated miRNA gene in lung
adenocarcinomas with oncogenic function and suggested
that aberrant miRNA gene methylation might contribute
to the human cancer epigenome [42].
Mayr et al. reported that the chromosomal translocations
associating with human tumors disrupted the repression
of High mobility group A2 (Hmga2) by let-7 miRNA. They
found that the loss of miRNA-directed repression of an
oncogene provided a mechanism for tumorigenesis, and
disrupting a single miRNA-target interaction could pro-
duce an observable phenotype in mammalian cells [43].
Lee and Dutta also demonstrated that ectopic expression
of let-7 miRNA reduced Hmga2 and cell proliferation in
lung cancer cell. Their results suggested that some tumors
activated the oncogene through chromosomal transloca-
tions that eliminated the oncogene's 3' untranslated
region with the let-7 miRNA target sites [44]. Hebert et al.
reported that Hmga2 expression in head and neck squa-
mous cell carcinoma cells was regulated in part by miR-98.
They showed that the transfection of pre-miR-98 during
normoxia diminished Hmga2 and potentiate resistance to
doxorubicin and cisplatin. Their findings implicated the
role of miR-98 as a key element in modulating tumors
during hypoxia [45].
Stem cells have the ability to escape cell cycle stop signals,
which are similar to cancer cells. On the basis of cell cycle
markers and genetic interactions, Harfield et al. reported
that dicer-1 mutant germline stem cells were delayed in
the G1 to S transition, which was dependent on the cyclin-
dependent kinase inhibitor dacapo, suggesting that miR-
NAs were required for stem cells to bypass the normal G1/
S checkpoint. The miRNA pathway might be part of a
mechanism that made stem cells insensitive to environ-
mental signals that normally stop the cell cycle at the G1/
S transition [46].
The role of microRNAs in cancer diagnosis
Lu et al. used a bead-based flow cytometric miRNA expres-
sion profiling method to present a systematic expression
analysis of miRNAs from human cancer samples, includ-
ing colon, liver, pancreas and stomach cancers. The
miRNA expression profiles were able to successfully clas-
sify poorly differentiated tumors. Their findings high-
lighted the potential of miRNA profiling in cancer
diagnosis [47].
Analyzing the entire miRNAome in pituitary adenomas
and in normal pituitary samples by microarray and RT-
PCR, Bottoni et al. showed that miRNA expression could
differentiate micro- from macro-adenomas and the
treated from non-treated patient samples. Several miRNAs
were involved in cell proliferation and apoptosis. Predic-
tive miRNAs could be potentially useful diagnostic mark-
ers, improving the classification of pituitary adenomas
[48].
With the application of in situ RT-PCR, Lee et al. showed
that the aberrantly expressed miR-221, miR-301 and miR-
376a were localized to pancreatic cancer cells but not to
stroma or normal acini or ducts. Aberrant miRNA expres-
sion offered new clues to pancreatic tumorigenesis and
might provide diagnostic biomarkers for pancreatic can-
cer [49].
The role of microRNAs in cancer prognosis
Takamizawa et al. reported that expression of let-7 miRNA
was frequently reduced in human lung cancers, and that
reduced let-7 miRNA expression was significantly associ-
ated with shorter postoperative survival. In addition, over-
expression of let-7 miRNA in A549 lung adenocarcinoma
cell line inhibited lung cancer cell growth in vitro. Their
study reported the potential clinical and biological effects
of let-7 miRNA alteration [50]. Yanaihara et al. identified
miRNA expression profiles which could discriminate lung
cancers from noncancerous lung tissues as well as molec-
ular signatures that differed in tumor histology. High hsa-
miR-155 and low hsa-let-7a-2 precursor miRNA expression
were found to be correlated with poor survival of lung
adenocarcinomas. Their results indicated that miRNAMolecular Cancer 2007, 6:60 http://www.molecular-cancer.com/content/6/1/60
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expression profiles were not just diagnostic markers, but
also prognostic markers of lung cancer [51].
Roldo et al. showed that the overexpression of miR-21 in
pancreatic tumors was strongly associated with both high
Ki67 proliferation index and the presence of liver metasta-
sis. Their results suggested that the alteration in miRNA
expression was related to progression of malignancy [25].
On the other hand, Bloomston et al. compared the expres-
sion pattern of miRNAs in pancreatic cancer with those of
normal pancreas and chronic pancreatitis using miRNA
microarrays. Differentially expressed miRNAs were identi-
fied which could differentiate pancreatic cancer from nor-
mal pancreas, chronic pancreatitis, or both. High
expression of miR-196a-2 was found to predict poor sur-
vival [52].
Perspective
Discovery of the role of miRNAs in various pathological
processes has opened up possible applications in molecu-
lar diagnostics and prognostics, particularly for cancer.
Some miRNAs are controlled by epigenetic alterations in
cancer cells, including DNA methylation and histone
modification. Using chromatin modifying drugs to acti-
vate tumor suppressor miRNAs can regulate target onco-
genes, and it may lead to novel cancer therapies in the
future. miRNAs can  complement other genomic and pro-
teomic biomarkers for cancer diagnosis and prognosis
[53,54]. Although each miRNA can control hundreds of
target genes, it remains a great challenge to identify the
accurate miRNA targets for cancer research. On the other
hand, as stem cells can regenerate and develop into many
different cell types in the body, they are always a focus of
intense research interest. It has been reported that miRNA
pathway plays a regulatory role in stem cell division,
whether this mechanism will contribute to prevent and
treat cancer will be worth studying [55].
The Nobel Prize in Physiology or Medicine 2006 was
awarded to Andrew Fire and Craig Mello for their discov-
ery of RNA interference (RNAi) – gene silencing by dou-
ble-stranded RNA. Since regulatory trans-acting antisense
RNAs has been found to exist in several species, posttran-
scriptional regulation of genes is no longer regarded as an
odd regulatory mechanism. miRNAs repress their target
mRNAs by complementary base pairing and induction of
the RNAi pathway. The discovery of hundreds of miRNAs
has raised the overall field of biomedical RNAi to a strik-
ing level of the current recognition. Attention has been
focused on the study of antisense oligonucleotide
approaches to inhibit miRNA function and small interfer-
ing RNA-like technologies for the replacement of miR-
NAs. Scientists try to unravel the mystery of miRNA
biology and explore its potential as therapeutic agents.
Large high-throughput studies in patients have revealed
that oncomiRs profiling can classify cancers and predict
patient outcomes with high accuracy. High-throughput
target analysis combining genomics, miRomics and pro-
teomics might help delineating the spectrum of targets
that are regulated by miRNAs. New knowledge about the
functional roles of oncomiRs is revolutionizing cancer
biology and will open up new opportunities in biomedi-
cal research.
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